Expressions of UHRF1, P53 and their clinical significances in colon carcinoma

doi:10.3760/cma.j.issn.1673422X.2016.05.007

Abstract

Abstract: ObjectiveTo investigate the expression levels and clinical significances of ubiquitinlike with PHD and ring finger domains 1 (UHRF1) and P53 in colon carcinoma. MethodsThe expressions of UHRF1 and P53 in 70 colon cancer tissues and 30 normal colon ones were detected by means of immunohistochemistry to analyze the correlation of these two proteins in the occurrence and development of colon carcinoma, and the relationship between their expressions and clinicopathological factors as well as prognosis was discussed. ResultsThe expression levels of UHRF1 and P53 in cancer tissues were significantly higher than those of canceradjacent tissues (87.1% vs. 56.7%, χ2=11.366, P=0.001; 64.3% vs. 6.7%, χ2=27.988, P=0.000) and showed a positive correlation between the two proteins (r=0.248, P=0.038). Both UHRF1 and P53 were associated with TNM stages (χ2=4.426, P=0.049; χ2=6.000, P=0.016) and the depth of invasion (χ2=12.553, P=0.002; χ2=4.904, P=0.036). However, they were irrelevant with the age (χ2=0.473, P=0.494; χ2=0.090, P=0.799) and gender (χ2=2.297, P=0.166; χ2=0.512, P=0.617) of patients, as well as the size (χ2=0.638, P=0.481; χ2=2.392, P=0.215) and histological grading of tumors (χ2=2.088, P=0.352; χ2=0.303, P=0.859). KaplanMeier analysis showed that the median survival time of patients with UHRF1, P53 positive expression was 21.83 months that was lower than patients with UHRF1 positive expression of 24.49 months (Z=－0.624, P=0.533). Both former of which was distinctly lower than that of negative ones of 37.33 months (Z=－2.856, P=0.004; Z=－2.694, P=0.007). ConclusionBoth UHRF1 and P53 are highly expressed in colon cancer tissues, which imply that UHRF1 and P53 may be strongly related with colon cancer development and can be a predictor for colon cancer prognosis.

Key words: Colon neoplasms, Tumor suppressor protein p53, Ubiquitinlike with PHD and ring finger domains 1

Ai Xiaoqing, Jia Xihua, Wang Xiaobo, Zheng Shujun, Zhao Xia, Zhang Bingxin. Expressions of UHRF1, P53 and their clinical significances in colon carcinoma[J]. Journal of International Oncology, 2016, 43(5): 346-349.

References

［1］ Kurkjian C, Kummar S, Murgo AJ. DNA methylation: its role in cancer development and therapy［J］. Curr Probl Cancer, 2008, 32(5): 187-235. DOI: 10.1016/j.currproblcancer.2008.08.002. ［2］ Obata Y, Furusawa Y, Endo TA, et al. The epigenetic regulator Uhrf1 facilitates the proliferation and maturation of colonic regulatory T cells［J］. Nat Immunol, 2014, 15(6): 571-579. DOI: 10.1038/ni.2886. ［3］ Nishiyama A, Yamaguchi L, Sharif J, et al. Uhrf1dependent H3K23 ubiquitylation couples maintenance DNA methylation and replication［J］. Nature, 2013, 502(7470): 249-253. DOI: 10.1038/nature12488. ［4］ Tien AL, Senbanerjee S, Kulkarni A, et al. UHRF1 depletion causes a G2/M arrest, activation of DNA damage response and apoptosis［J］. Biochem J, 2011, 435(1): 175-185. DOI: 10.1042/BJ20100840. ［5］ Chae HD, Kim SY, Park SE, et al. p53 and DNAdependent protein kinase catalytic subunit independently function in regulating actin damageinduced tetraploid G1 arrest［J］. Exp Mol Med, 2012, 44(3): 236-240. DOI: 10.3858/emm.2012.44.3.018. ［6］ Mudbhary R, Hoshida Y, Chernyavskaya Y, et al. UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma［J］. Cancer Cell, 2014, 25(2): 196-209. DOI: 10.1016/j.ccr.2014.01.003. ［7］ Kim MY, Park SJ, Shim JW, et al. Naphthazarin enhances ionizing radiationinduced cell cycle arrest and apoptosis in human breast cancer cells［J］. Int J Oncol, 2015, 46(4): 1659-1666. DOI: 10.3892/ijo.2015.2857. ［8］ Geng Y, Gao Y, Ju H, et al. Diagnostic and prognostic value of plasma and tissue ubiquitinlike, containing PHD and RING finger domains 1 in breast cancer patients［J］. Cancer Sci, 2013, 104(2): 194-199. DOI: 10.1111/cas.12052. ［9］周碧芳, 邓斐, 周学惠, 等. UHRF1基因在人卵巢癌细胞株OVCAR3中的表达及意义［J］. 现代妇产科进展, 2012, 21(10): 748-751. ［10］ Wang F, Yang YZ, Shi CZ, et al. UHRF1 promotes cell growth and metastasis through repression of p16(ink4a) in colorectal cancer［J］. Ann Surg Oncol, 2012, 19(8): 2753-2762. DOI: 10.1245/s1043401121941. ［11］ Jones PA, Baylin SB. The epigenomics of cancer［J］. Cell, 2007, 128(4): 683-692. DOI: 10.1016/j.cell.2007.01.029 . ［12］ Fleuriel C, Touka M, Boulay G, et al. HIC1 (hypermethylated in cancer 1) epigenetic silencing in tumors［J］. Int J Biochem Cell Biol, 2009, 41(1): 26-33. DOI: 10.1016/j.biocel.2008.05.028. ［13］ Arima Y, Hirota T, Bronner C, et al. Downregulation of nuclear protein ICBP90 by p53/p21Cip1/WAF1dependent DNAdamage checkpoint signals contributes to cell cycle arrest at G1/S transition［J］. Genes Cells, 2004, 9(2): 131-142.

[1]	Liu Jin, Chen Xiang, Ma Qun, Tong Dongdong. Study on expression relationship of DNA methyltransferase 1 and forkhead box O3a in colon cancer [J]. Journal of International Oncology, 2021, 48(12): 735-738.
[2]	Yu Xuejuan, An Hongwei, Sun Yamei, Jiang Zheng, Zhang Xuehai, Yang Wenjing, Zhang Wei. Expressions of MMP2, TIMP2, Ki-67 and P53 in glioma tissues and their significance [J]. Journal of International Oncology, 2019, 46(12): 718-722.
[3]	YUAN Yang-Jun, LU Da-Song, DENG Bing-Qu. Expression of CIAPIN1 protein in colon cancer and its relationship with pathological features of tumor [J]. Journal of International Oncology, 2018, 45(8): 483-486.
[4]	Shen Qinglin, Song Qibin, Zhang Bicheng, Yao Yi, Xu Tangpeng, Chu Yuxin, Peng Min. Effects of microRNA-134 on proliferation and apoptosis of non-small cell lung cancer by regulating P53 protein [J]. Journal of International Oncology, 2018, 45(11): 647-651.
[5]	LAI Jun, LUO Lin. Expression and clinical significance of MGMT, Ki 67 and P53 in human gliomas [J]. Journal of International Oncology, 2015, 42(3): 169-171.
[6]	HOU Qing-Sheng, ZHANG Yu-Lin, CHEN De-Xi, GUO Hong-Liang. Role of P53 outside the nucleus [J]. Journal of International Oncology, 2012, 39(8): 665-668.